Memic Innovative Surgery Ltd 

  Early Stage Capital  

  

  Athena  

WARNING

The law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors make an informed decision.

If you are an accredited investor under the definition of that term in Rule 501(a) of Regulation D of the US Securities Act of 1933, the usual rules do not apply to offers of financial products made to you. As a result, you may not receive a complete and balanced set of information.

You will also have fewer other legal protections for these investments. Ask questions, read all documents carefully, and seek independent financial advice before committing yourself.


Overview

An opportunity exists for wholesale investors to register interest to invest in Memic Innovative Surgery Limited (“Memic”). 


Background

Memic is seeking USD60m on a most recent pre-money valuation of USD150m, with proceeds to be applied to sales & marketing, R&D/ IP, clinical development & regulatory, manufacturing scale up and general costs

Memic has set out to transform robot-assisted surgery, with proprietary technology that has the potential to far surpasses today’s best solutions. This has been delivered by Memic’s Hominis™ which can provide unprecedented access and manoeuvrability. Its surgical platform features miniature, humanoid-shaped robotic arms with human dexterity, superhuman flexibility, and 360˚ articulation for various access configurations. It is dramatically smaller, more versatile and less costly than current robotic platforms and the technology opens up a host of minimally-invasive procedures that until now have been off-limits to robot-assisted surgery.

Some pipeline indications include abdominal single and multi-port surgery, as well as procedures performed in a trans-oral approach. Memic envisions a near future where numerous indications – and millions of patients – will benefit from these disruptive capabilities.


People

Maurice R. Ferré, MD has been appointed as chairman of Memic’s board of directors, following the company’s latest USD10m investment round. Signing on as a private investor, Mr. Ferré has over 20 years of experience in the medical device industry. He currently serves as CEO and chairman of the board of directors of INSIGHTEC, which delivers incisionless surgery using focused ultrasound guided by MRI.

A longtime innovator and entrepreneur, Dr. Ferré has founded and managed several world-leading companies in the field of precision, robotic, and image-guided surgery, making him ideally suited to chair Memic’s unique robot-assisted surgical technology.


Regulatory Approval

The company is in a process seeking the appropriate FDA approvals – the capital raise is subject to those approvals being received.

An overview of the company and its initiatives can be accessed in Documents as can a timeline of the FDA approval process.


Summary of Investment highlights:

  • Transformational robotic surgery technology
  • Technology developed and will be available at considerably lower cost to alternatives
  • Proven, successful leadership team with track record of successfully developing and commercialising medical technology
  • Capital invested subject to FDA approval


To visit Memic’s website click here.


The PPM will be made available on registration of interest. 


Issue Type:
Early Stage Capital
Sector:
Health Care
isEOI: true

Investment Details

Investment Type: Wholesale

Wholesale Investment Type: NZ Wholesale Equities

Transaction Size:USD 60,000,000.00

Committed Capital: 

Pre-money valuation: 

Minimum Capital Raise: 

Share Price:USD 1.00

Unit Price:USD 0.00

Minimum Investment Size:USD 50,000.00

Document Name Description Date Uploaded
Memic Regulatory Overview - December 2019 3 July 2020 Preview/Download
Memic Company Presentation - June 2020 3 July 2020 Preview/Download
Zoom: 0

You do not have any investments to report on.

No trade history available for this issue.

Secondary Market - Memic Innovative Surgery Ltd Wholesale

No secondary market listings for this issue availble at this time. Check the Exchange for more listings.